Bioventus Stock Today
| BVS Stock | USD 9.09 0.34 3.61% |
PerformanceVery Weak
| Odds Of DistressLow
|
Bioventus is selling for under 9.09 as of the 27th of March 2025; that is 3.61 percent decrease since the beginning of the trading day. The stock's lowest day price was 8.97. Bioventus has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of December 2024 and ending today, the 27th of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 11th of February 2021 | Category Healthcare | Classification Health Care |
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the bodys natural healing process in the United States and internationally. The company was founded in 2011 and is headquartered in Durham, North Carolina. The company has 66.16 M outstanding shares of which 867.79 K shares are currently shorted by investors with about 1.92 days to cover. More on Bioventus
Moving against Bioventus Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Bioventus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Robert Claypoole | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Vistry Group PLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, HNX 30, HNX, NASDAQ Composite, NASDAQ Health Care, SPASX All Technology, Australia All Ordinaries, HNX Large Cap, HNX Financials, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt LevelsBioventus can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bioventus' financial leverage. It provides some insight into what part of Bioventus' total assets is financed by creditors.
LiquidityBioventus has 27.34 M in debt with debt to equity (D/E) ratio of 1.17, which is OK given its current industry classification. Bioventus has a current ratio of 0.92, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Bioventus to invest in growth at high rates of return.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bioventus (BVS) is traded on NASDAQ Exchange in USA. It is located in 4721 Emperor Boulevard, Durham, NC, United States, 27703 and employs 930 people. Bioventus is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 623.86 M. Bioventus runs under Health Care Equipment & Supplies sector within Health Care industry. The entity has 66.16 M outstanding shares of which 867.79 K shares are currently shorted by investors with about 1.92 days to cover.
Bioventus has about 34.36 M in cash with 38.8 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56.
Check Bioventus Probability Of Bankruptcy
Ownership AllocationBioventus holds a total of 66.16 Million outstanding shares. Over half of Bioventus' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Bioventus Ownership Details
Bioventus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Royce & Associates, Lp | 2024-12-31 | 732.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 642.6 K | |
| Oberweis Asset Management Inc | 2024-12-31 | 601.7 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 435.3 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 427.4 K | |
| Ophir Asset Management Pty Ltd | 2024-12-31 | 424.7 K | |
| Renaissance Technologies Corp | 2024-12-31 | 388.7 K | |
| Millennium Management Llc | 2024-12-31 | 370.8 K | |
| Segall Bryant & Hamill | 2024-12-31 | 352.6 K | |
| Essex Woodlands Health Ventures | 2024-12-31 | 13 M | |
| Juniper Investment Co, Llc | 2024-12-31 | 6.9 M |
Bioventus Historical Income Statement
Bioventus Stock Against Markets
Bioventus Corporate Management
| Anthony JD | General VP | Profile | |
| Kenneth Reali | CEO Director | Profile | |
| MBA BS | Senior Operations | Profile | |
| Helen Leupold | Senior Officer | Profile | |
| Katrina Church | VP Officer | Profile | |
| Alessandraa Pavesio | VP Officer | Profile |
Additional Tools for Bioventus Stock Analysis
When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.